Work

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

Year: 2009

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v114.22.2731.2731

Authors: Michelle Fanale, Nancy L Bartlett, Andres Forero-Torres, Joseph Rosenblatt, Sandra J Horning, Anna R Franklin, Carmel M Lynch, Eric L Sievers, Dana A Kennedy

Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, University of Alabama at Birmingham, University of Miami, Sylvester Comprehensive Cancer Center, Stanford Medicine, Seagen (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2577583147

FWCI: 6.511

Cites:

Cited by: 36

Related to: 10